➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Johnson and Johnson
Baxter
Dow

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Lumacaftor


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Lumacaftor?

Lumacaftor is an investigational drug.

There have been 34 clinical trials for Lumacaftor. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Lung Diseases. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, Massachusetts General Hospital, and National Heart, Lung, and Blood Institute (NHLBI).

There are ninety-eight US patents protecting this investigational drug and nine hundred and thirty-nine international patents.

Recent Clinical Trials for Lumacaftor
TitleSponsorPhase
Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationVertex Pharmaceuticals IncorporatedPhase 3
Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.Assistance Publique - Hôpitaux de ParisN/A
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240University of North CarolinaEarly Phase 1

See all Lumacaftor clinical trials

Clinical Trial Summary for Lumacaftor

Top disease conditions for Lumacaftor
Top clinical trial sponsors for Lumacaftor

See all Lumacaftor clinical trials

US Patents for Lumacaftor

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lumacaftor   Start Trial Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
Lumacaftor   Start Trial Modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
Lumacaftor   Start Trial Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
Lumacaftor   Start Trial Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-- fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxa- mide Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
Lumacaftor   Start Trial Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
Lumacaftor   Start Trial Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
Lumacaftor   Start Trial Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lumacaftor

Drugname Country Document Number Estimated Expiration Related US Patent
Lumacaftor Australia 2015229117 2034-03-13   Start Trial
Lumacaftor Canada 2942387 2034-03-13   Start Trial
Lumacaftor European Patent Office 3116870 2034-03-13   Start Trial
Lumacaftor World Intellectual Property Organization (WIPO) 2015138934 2034-03-13   Start Trial
Lumacaftor Australia 2007235260 2026-04-07   Start Trial
Lumacaftor Brazil PI0710965 2026-04-07   Start Trial
Lumacaftor Canada 2648719 2026-04-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.